98 related articles for article (PubMed ID: 22296308)
1. Oral delivery of particulate prostate cancer vaccine: in vitro and in vivo evaluation.
Akalkotkar A; Tawde SA; Chablani L; D'Souza MJ
J Drug Target; 2012 May; 20(4):338-46. PubMed ID: 22296308
[TBL] [Abstract][Full Text] [Related]
2. Oral microparticulate vaccine for melanoma using M-cell targeting.
D'Souza B; Bhowmik T; Shashidharamurthy R; Oettinger C; Selvaraj P; D'Souza M
J Drug Target; 2012 Feb; 20(2):166-73. PubMed ID: 21981679
[TBL] [Abstract][Full Text] [Related]
3. Development of a microparticulate prostate cancer vaccine and evaluating the effect of route of administration on its efficacy via the skin.
Akalkotkar A; Chablani L; Tawde SA; D'Souza C; D'Souza MJ
J Microencapsul; 2015; 32(3):281-9. PubMed ID: 25985824
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery.
Tawde SA; Chablani L; Akalkotkar A; D'Souza MJ
J Control Release; 2016 Aug; 235():147-154. PubMed ID: 27238440
[TBL] [Abstract][Full Text] [Related]
5. Spray-dried microparticles: a potential vehicle for oral delivery of vaccines.
Chablani L; Tawde SA; D'Souza MJ
J Microencapsul; 2012; 29(4):388-97. PubMed ID: 22283700
[TBL] [Abstract][Full Text] [Related]
6. Formulation and evaluation of oral microparticulate ovarian cancer vaccines.
Tawde SA; Chablani L; Akalkotkar A; D'Souza C; Chiriva-Internati M; Selvaraj P; D'Souza MJ
Vaccine; 2012 Aug; 30(38):5675-81. PubMed ID: 22750042
[TBL] [Abstract][Full Text] [Related]
7. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of antigens to the gut-associated lymphoid tissues: 2. Ex vivo evaluation of lectin-labelled albumin microspheres for targeted delivery of antigens to the M-cells of the Peyer's patches.
Akande J; Yeboah KG; Addo RT; Siddig A; Oettinger CW; D'Souza MJ
J Microencapsul; 2010; 27(4):325-36. PubMed ID: 20055749
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
10. In vitro and ex vivo characterization of lectin-labeled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery.
Yeboah KG; Akande J; Addo RT; Siwale RC; Aninkorah-Yeboah K; Siddig A
J Drug Target; 2014 Jan; 22(1):34-47. PubMed ID: 23987115
[TBL] [Abstract][Full Text] [Related]
11. Oral ingestion of cow's milk immunoglobulin G stimulates some cellular immune systems and suppresses humoral immune responses in mouse.
Ohnuki H; Mizutani A; Otani H
Int Immunopharmacol; 2006 Aug; 6(8):1315-22. PubMed ID: 16782545
[TBL] [Abstract][Full Text] [Related]
12. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
Schroten C; Scheffer R; Boon L; de Ridder CM; Bangma CH; Kraaij R
J Immunother; 2012; 35(2):125-30. PubMed ID: 22306900
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
16. Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen.
Bhowmik T; D'Souza B; Uddin MN; D'Souza MJ
J Drug Target; 2012 May; 20(4):364-71. PubMed ID: 22339323
[TBL] [Abstract][Full Text] [Related]
17. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
19. Targeting of mucosal vaccines to Peyer's patch M cells.
Frey A; Neutra MR
Behring Inst Mitt; 1997 Feb; (98):376-89. PubMed ID: 9382762
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral vs. parenteral cyclophosphamide on in vitro IgA and IgG production by murine Peyer's patches and cultured jejunal fragments.
Karacic JJ; Cowdery JS
Immunopharmacol Immunotoxicol; 1987; 9(4):441-65. PubMed ID: 3501798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
